P1675: SUTIMLIMAB PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: OPEN-LABEL EXTENSION OF THE PHASE 3 CADENZA STUDY

• Alexander Röth,
• Catherine M Broome,
• Wilma Barcellini,
• Bernd Jilma,
• Quentin A Hill,
• David Cella,
• Tor Henrik Anderson Tvedt,
• Masaki Yamaguchi,
• Irina Murakhovskaya,
• Michelle Lee,
• Frank Shafer,
• Marek Wardęcki,
• Deepthi Jayawardene,
• Ronnie Yoo,
• Jerome Msihid,
• Ilene C Weitz

Affiliations

Alexander Röth

1 University Hospital Essen, University of Duisburg-Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, Essen, Germany

Catherine M Broome

2 MedStar Georgetown University Hospital, Division of Hematology, Washington DC, United States

Wilma Barcellini

3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Bernd Jilma

4 Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

Quentin A Hill

5 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

David Cella

6 Department of Medical Social Sciences, Center for Patient-Centered Outcomes, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States

Tor Henrik Anderson Tvedt

7 Haukeland University Hospital, Section for Hematology, Department of Medicine, Bergen, Norway

Masaki Yamaguchi

8 Ishikawa Prefectural Central Hospital, 金沢市, Japan

Irina Murakhovskaya

9 Albert Einstein College of Medicine, Montefiore Medical Center, Department of Hematology and Oncology, Bronx, United States

Michelle Lee

10 Sanofi, Bridgewater, United States

Frank Shafer

10 Sanofi, Bridgewater, United States

Marek Wardęcki

11 Sanofi, Warsaw, Poland

Deepthi Jayawardene

12 Sanofi, Cambridge, MA, United States

Ronnie Yoo

13 Sanofi, Cambridge, MA, United States

Jerome Msihid

14 Sanofi, Chilly-Mazarin, France

Ilene C Weitz

15 Keck School of Medicine of USC, Los Angeles, CA, United States